Evaluation of intralesional steroid theraphy in patients suffered from oral sub mucous fibrosis (OSMF)
Dr. Sonu Kumar Singh, Dr. Satyendra Sharma
Instruct patients regarding the importance of discontinuing the habit of chewing betel quid. Inform patients that eliminating tobacco from the quid product may reduce the risk of oral cancer. Instruct patients to avoid spicy foodstuffs. Instruct patients to eat a complete and healthy diet to avoid malnutrition. Instruct patients regarding maintaining proper oral hygiene and scheduling regular oral examinations. Intervention studies and public health campaigns against oral habits linked to oral submucous fibrosis may be the best way of controlling the disease at the community level. Educate the community regarding the local adverse effects of chewable agents, which although not inhaled, are still not harmless. Hence based on above findings the present study was planned for Evaluation of Intralesional Steroid Theraphy in Patients Suffered from Oral Sub Mucous Fibrosis (OSMF). The present study was planned in Department of ENT, Nalanda Medical College and Hospital Patna, Bihar, India. The study was conducted from September 2018 to February 2019. Total 30 cases of OSMF were enrolled in the present study. The patients were divided in three study groups as Group I, II and III. Occupational history and personal history with special preference to betel nut chewing, smoking, drinking alcohol was taken. Routine blood test, blood sugar, urine examination and HIV test was done to detect any systemic disease and immunocompromised conditions. The data generated from the present study concludes that Ultrasound therapy for 15 days improved both mouth opening and burning sensation in OSMF patients, but ultrasound therapy alone was found to have less reduction of burning sensation when compared with combination treatment and only intralesional infiltration of 2 ml dexamethasone (4 mg/ml) and hyaluronidase (1500 IU) treatment. Ultrasound therapy showed synergistic effect in combination with intralesional infiltration of 2 ml dexamethasone (4 mg/ml) and hyaluronidase (1500 IU) by enhancing their absorption into the tissues.